ロングリードシーケンスによるバイオ医薬品研究開発のROI最大化

What is Long-Read Sequencing?

Long-read sequencing is a genomic sequencing technology that enables the reading of long stretches of DNA or RNA, from 1,000 to over 20,000 bases, in a single pass. Unlike short-read sequencing, which analyses shorter fragments (typically 50 to 300 bases), long-read sequencing captures entire regions in a single read, significantly reducing the need for complex assembly.

This ability to sequence native, unamplified DNA or RNA molecules makes long-read sequencing particularly valuable for studying complex genomic regions, such as those with high GC content, repetitive elements, or structural variation. It has become a powerful quality control tool, especially in areas where short-read technologies often fall short. By preserving the integrity of native sequences, long-read approaches provide richer, more reliable genetic insights.

Storage and Management Data

The substantial and ultra-rich data generated by long-read sequencing far exceeds the volume generated by short-read platforms. These large files require an advanced data storage infrastructure that can handle both the size and complexity of the data. Efficient data management solutions are essential to ensure scalability, maintain performance, and enable secure access and sharing. Without such systems, organizations can experience data bottlenecks, slow processing times, and increased infrastructure maintenance costs.

Data Validation and Reliability

While the accuracy of long-read sequencing has improved significantly, especially with high-fidelity (HiFi) reads, ensuring the reliability of the data often requires additional validation steps. Compared to short-read sequencing platforms, which benefit from well-established workflows, long-read data may require supplemental sequencing or computational validation to confirm results, particularly in regulatory-compliant environments such as clinical genomics or biopharma manufacturing applications.

Risks and Limitations of Outsourcing

Outsourcing long-read NGS-based assays presents several strategic and operational challenges. It often requires a significant investment of time and resources and poses intellectual property (IP) risks that can delay project timelines. Analytical R&D teams may not have full access to raw sequencing data, limiting their ability to perform in-depth analyses or respond to unexpected findings, an issue that can complicate regulatory submissions. In addition, inconsistencies in assay standardization, transparency, and data quality across external providers can lead to unreliable decision-making. Communication gaps, logistical barriers, and challenges with data transfer protocols and quality control further impede efficiency, increasing overall project complexity and cost.